Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Opioid-Related Disorders Age between 18 and 60 2. Evidence of physical dependence on opioids (self-report, urine screen, physical exam) 3. Seeking treatment for opioid dependence 4. Able to attend treatment clinic 7 days/week  General- 1. Poor venous access 2. Urologic conditions that would inhibit urine collection 3. Pregnancy or breastfeeding 4. Failure to agree to use a medically effective form of contraception while in the study (in women who are sexually active with a male partner and able to get pregnant). Acceptable forms of contraception for this study hormonal contraceptives (birth control pills, injectable hormones, vaginal ring hormones), surgical sterility (tubal ligation or hysterectomy); IUD; Diaphragm with spermicide; Condom with spermicide 5. Current physical dependence on alcohol or sedative-hypnotics, e.g. benzodiazepines Psychiatric- 1. Cognitive impairment severe enough to preclude informed consent or valid responses on questionnaires (Shipley Institute of Living scale estimated full-scale IQ less than 80) 2. History of schizophrenia or any other DSM-IV psychotic disorder 3. History of bipolar disorder 4. Current Major Depressive Disorder Medical- 1. Any active or untreated medical illness that in the view of the investigators would compromise participation in research 2. Allergy or intolerance to either buprenorphine or clonidine 3. Cerebrovascular disease 4. Conduction disturbances (e.g., second-degree heart block, third-degree heart block, atrial fibrillation, ventricular tachycardia) or arrhythmias 5. Myocardial infarction, or documented coronary artery disease 6. Congestive heart failure 7. Chronic renal failure, as estimated by Cr > 2.0 8. CD4 < 200 or evidence of severely compromised immune system /AIDS 9. Marked, sustained bradycardia (HR < 45 bpm) on three separate occasions 10. Marked, sustained low blood pressure (SBP <95 or DBP < 40 mm Hg) over three separate readings 11. Marked, sustained high blood pressure (SBP >160 mm Hg, DBP >100 mm Hg) over several readings, without being on antihypertensive medications. 12. ECG changes suggestive of acute ischemia, clinical important arrhythmia, left bundle branch block, or other changes that concerns the MRP will the participant. If accompanied by cardiovascular complaints such as chest pain or syncope, less specific ECG findings will also the patient. When in doubt, the ECG will be sent to cardiology on a prn basis for a manual reading. 13. Orthostatic hypotension (upon standing for 3 minutes, there is a 20 mm Hg decrease in systolic blood pressure or a 10 mmHg decrease in diastolic blood pressure accompanied by an increase by 20 bpm in heart rate) on two separate readings. Taking contraindicated medications- 1. Beta blockers 2. Tricyclic antidepressants 3. Antipsychotics 4. Mah huang 5. Yohimbe 6. Ephedra 7. Sildenafil citrate (Viagra). Sildenafil citrate doses > 25mg should not be taken within 4 hours of taking an alpha blocker or it can produce significant and symptomatic hypotension (Pfizer). Of note, Viagra, like buprenorphine, is metabolized by cytochrome P450 3A4. Ingestion of buprenorphine could potentate the effects of sildenafil citrate which could extent the period of safety to > 4 hrs from when an alpha blocker could be taken after Viagra ingestion. Family history of sudden cardiac death at age < 50 Lab Test and Lab Values: WBC* < 1,500 > 13,000 #/CUMM HCT < 33 > 49 Percent Platelets < 100 > 500 K/CUMM Sodium < 132 > 149 MEQ/L Potassium < 3.5 > 5.2 MEQ/L Calcium < 8.4 > 10.5 MG/DL Magnesium < 1.3 > 3 MG/DL <TAB> BUN > 35 MG/DL Cr<TAB> > 2.0 MG/DL <TAB> Alk Phos<TAB> > 200 U/L AST<TAB> > 200 U/L ALT<TAB> > 200 U/L GGT<TAB> > 400 U/L Albumin<TAB> < 3 GM/DL Total bilirubin > 2.0 MG/DL Direct bilirubin > 0.4 MG/DL TSH<TAB> < 0.27 > 4.2 UIU/ML <TAB> *Leukocytosis will prompt further investigation before clearance.<TAB>